The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Fully equipped labs with 75-member team set-up and made operational in <100 days
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
The combination will support clients in getting their end-to-end discovery and development programs delivered.
The company has announced net revenue of Rs. 639.8 crore for Q3 FY23 as compared to Rs. 562.08 crore in the corresponding period of the previous year
The company is one of the most profitable companies manufacturing speciality chemicals in India
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
Subscribe To Our Newsletter & Stay Updated
